Checkpoint Therapeutics’ unloxcyt approved by FDA

On December 13, the FDA approved cosibelimab-ipdl (unloxcyt), a programmed death ligand-1 blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.